Table 4.

Risk of CRA ¹ based on percentile levels (33% and 66%) of vitamin D metabolites, IGF-1 ², and IGFBP-3 ³.

	OR (95% CI) 4	p	Adjusted OR (95% CI) (a)	p (a)	Q-Value (b)
Cholecalciferol ≤ 64.4 ng/mL	4.63 (1.67–12.7)	0.004	3.858 (1.33–12.68)	0.017	0.07
Cholecalciferol ≥ 78.34 ng/mL	0.68 (0.28–1.71)	0.47	1.53 (0.58–4.08)	0.38
Calcidiol ≤ 16.23 pg/mL	0.63 (0.26–1.54)	0.35	0.67 (0.25–1.79)	0.78
Calcidiol ≥ 22.94 pg/mL	0.68 (0.28–1.71)	0.47	1.49 (0.56–4.01)	0.41
Calcitriol ≤ 31.87 pg/mL	1.54 (0.62–3.81)	0.47	1.23 (0.46–3.43)	0.67
Calcitriol ≥ 40.64 pg/mL	0.68 (0.28–1.71)	0.47	1.57 (0.59–4.20)	0.35
IGF-1 ≤ 51.9 ng/mL	1.54 (0.62–3.81)	0.47	0.92 (0.31–2.76)	0.89
IGF-1 ≥ 78.62 ng/mL	0.87 (0.36–2.27)	0.81	0.90 (0.31–2.49)	0.84
IGFBP-3 ≤ 1.82 mcg/mL	1.9 (0.78–5.28)	0.23	1.43 (0.51–4.16)	0.49
IGFBP-3 ≥ 2.64 mcg/mL	0.72 (0.29–1.81)	0.63	1.32 (0.50–3.45)	0.56

¹ CRA—colorectal adenoma; ² IGF-1—insulin-like growth factor-1; ³ IGFBP-3—insulin-like growth factor binding protein-3; ⁴ OR—odds ratio. ^(a) ORs and p values adjusted for age, sex and smoking status; ^(b) Q-value < 0.10 using the False Discovery Rate adjustment for multiple testing.